Innovative marketing programs for the pharmaceutical industry
The Kalvistas Pharmaceuticals stock was up 1.2% to $1,814 per share on Friday.
The stock has been on a tear since its July 1 IPO, gaining 5.3% so far this year.
It’s been outperforming many other stocks.
In fact, Kalvistas shares were the highest of any pharmaceutical company in August.
The stock is up 9.7% in the last three months of the year.
There are currently no approved treatments for the condition, and many doctors who treat the disease are afraid to even ...
WYETH PHARMACEUTICALS, PFEIFFER, Pfizer, and Allergan have joined forces in a proposed $600 million partnership, the companies announced Wednesday.The agreement, ...
Updated October 10, 2018 07:51:28Lupin Pharmaceuticals announced in September that it had entered into a definitive agreement to acquire the ...
